2238 Knudsen, Karen E. - Jefferson Medical College - Thomas Jefferson University
kxk016

Karen E. Knudsen, PhD

Contact Dr. Knudsen

Kimmel Cancer Center
233 S. Tenth Street
Suite 1008
Philadelphia, PA 19107

(215) 503-8574

Most Recent Peer-reviewed Publications

  1. The role of tumor suppressor dysregulation in prostate cancer progression
  2. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes
  3. Dual roles of PARP-1 promote cancer growth and progression
  4. Cyclin D1 goes metabolic: Dual functions of cyclin D1 in regulating lipogenesis
  5. The AR dependent cell cycle: Mechanisms and cancer relevance
  6. Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression
  7. mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer
  8. Postprostatectomy radiation therapy: An evidence-based review
  9. FOXA1: Master of steroid receptor function in cancer
  10. Time to stratify? the retinoblastoma protein in castrate-resistant prostate cancer
  11. Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate
  12. The meaning of p16 ink4a expression in tumors: Functional significance, clinical associations and future developments
  13. Therapeutically activating RB: Reestablishing cell cycle control in endocrine therapy-resistant breast cancer
  14. Outsmarting androgen receptor: Creative approaches for targeting aberrant androgen signaling in advanced prostate cancer
  15. Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function
  16. A tale of three PKCs: Epsilon emerges as a driver of pre-neoplastic phenotypes
  17. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression
  18. RB-pathway disruption in breast cancer: Differential association with disease subtypes, disease-specific prognosis and therapeutic response
  19. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene
  20. Partners in crime: Deregulation of AR activity and androgen synthesis in prostate cancer
0